Integrated Biosciences

Something rare is happening at the intersection of AI, therapeutics, and aging biology — and we’re building the team to help shape it. @Integrated_Bio is hiring an Associate Director of Medicinal Chemistry, alongside several additional scientific roles. We’re looking for scientists who want to work on consequential problems with tools that didn't exist three years ago. We’re also hiring for: 🔬 Director of In Vivo Pharmacology 🧬 Senior Research Associate, In Vivo Pharmacology ⚗️ Senior Research Scientist, High Throughput Biology Integrated Biosciences is an AI-native drug discovery company developing therapeutics for age-related diseases. Explore roles & apply: integratedbio.com/contact/ #AI #biotech #drugdiscovery #aging #hiring

Thrilled to have our CSO, Dan Anderson, speaking at Computational Advances in Drug Discovery in London (May 7–10), hosted by Keystone Symposia. He’ll present our fully AI-native small molecule discovery engine built on complex cellular phenotypic models to show how we’re rethinking drug discovery at @IntegratedBio. Fantastic lineup including Karen Akinsanya @schrodinger, Najat Khan @RecursionPharma, Alexander Hillisch @UCBUSA, and Gang Liu @gatesfoundation . Join us in London: keysym.us/KSDrugDiscover…

Big news 🚀 @Yuhu_ai_, former co-founder of @xai, is joining @Integrated_Bio as a Scientific Advisory Board member. Tony helped build Grok into one of the world’s leading reasoning models and scaled Colossus, one of the most powerful AI training clusters ever created. Now we’re bringing that frontier AI firepower to aging biology. After an intense and productive collaboration applying state-of-the-art AI to drug discovery, we’re excited to welcome him to the team. Read more: integratedbiosciences.com/integrated-bio…

Congratulations to Prof. @UriAlonWeizmann of the Department of Molecular Cell Biology, upon being awarded the 2026 IUPAP Medal for the Physics of Life

Excited to welcome Dan Anderson, Ph.D. as CSO at @Integrated_Bio ! Dan brings 20+ years of experience building high-impact drug discovery teams, most recently as CSO at Eikon Therapeutics. He’ll lead our scientific strategy and pipeline development, advancing our optogenetics + chemistry +AI platform to turn discovery into medicines that can impact patients. 🔗 Full announcement: integratedbiosciences.com/integrated-bio… #Biotech #DrugDiscovery #Aging #AI

Last night at JPM: The Future of Aging. Co-hosted with Cooley + @Stifel, featuring our CEO @felixjwong alongside @bettslacroix (@RetroBio_), @jacobkimmel (@newlimit), @TimOpler (Stifel), Hanadie Yousef (Juvena Therapeutics), and Mike Nelson (Cooley).

From landmark publications (Nature Protocols, 2× Cell) to doubling our team and strengthening our platform, 2025 was a big year. We wrapped it up with our inaugural R&D Day, bringing together our team and collaborators to share rapid progress across our small-molecule pipeline for age-related diseases and our platform at the intersection of biology, chemistry, and AI. Heading into 2026 with momentum and ready to break new ground.

Welcome to 2026! @Princeton put together a fine story on some cutting-edge University research, including Dave MacMillan’s @MacMillan_Lab groundbreaking micromap technology. Enjoy the story here: bit.ly/4srFMR0

Excited to host The Future of Aging on Monday at JPM 2026! Expect insights, dynamic discussion, and networking over cocktails with senior leaders from pharma, biotech, venture, and healthcare innovation.

Today we’re sharing exciting new results showing that our computer vision models can infer cellular age from simple microscope images: at scale, at low cost, and with human interpretability built in. Our approach enables us to: ✅ Infer biological age with 91% accuracy on unseen human donors ✅ Recover ~90% of the signal from unstained brightfield images ✅ Use MONET to generate interpretable virtual cell paintings + timelapses ✅ Recover 89% of biological signal in MoA prediction tasks ✅ Screen ultra-large chemical libraries with low-cost microscopy 📄 Blog: integratedbiosciences.com/blog-scaling-c… 📄 MONET paper: arxiv.org/abs/2512.11928 🎥 Demo: thiscellpaintingdoesnotexist.com #Aging #DrugDiscovery #AI #ComputerVision #Biotech #Longevity @alex_peys @williamLberman @shv @UCSB

Aging was once seen as biological destiny. Not anymore. Nature proves longevity is programmable; embryogenesis shows human aging can reset to zero. Aging biology is now an engineering problem, and we’re building the tools to tackle it. Our latest blog breaks down how our three discovery strategies systematically target aging to uncover novel therapeutics. Read more: integratedbiosciences.com/blog-aging-as-…

Pharma R&D is hitting an inflection point. At #GapSummit2025, we joined @AstraZeneca, @NovoNordisk, @Microsoft, and @BCG to dig into where AI is already changing the game—from data-rich discovery to physics-driven modeling. Our belief at Integrated: the real breakthroughs will come from combining differentiated data, domain-tuned AI, and rigorous experimental validation. That fusion is already revealing new targets and compounds for age-related diseases. A fantastic panel and an exceptional summit at Cambridge. @Cambridge_Uni #DrugDiscovery #AI #Pharma #Aging #Innovation #Therapeutics #DeepLearning

We’re incredibly lucky to have Sir David MacMillan on our Scientific Advisory Board. In this short clip that his team at Princeton recorded for our R&D Day, Dave shares why he’s excited about Integrated Biosciences and why the science we’re building together matters. Dave is the James S. McDonnell Distinguished University Professor of Chemistry at Princeton and a 2021 Nobel Prize laureate for pioneering asymmetric organocatalysis. @dmac68 @shv @MIT @Harvard @Princeton @PrincetonChem #PrincetonChemistry #NobelPrize #Biotech #AgingScience #DeepTech #DrugDiscovery

Transforming correlations into causal clarity. Our co-founder and CSO Max Wilson shares how Integrated combines multi-omics, including proteomics, transcriptomics, and chromatin readouts, to uncover mechanisms that drive cellular aging and resilience, fueling the discovery of therapeutics for  age-related diseases. Read the article here: drugdiscoverynews.com/how-multi-omic… @maxzwilson @UCSB @illumina @illuminaventure @DrugDiscovNews @bullseyebio @SpectrumScience

A tremendous milestone for our Scientific Advisory Board member, Dr. Wendy Young! Her former colleagues at @genentech and @Roche have reported positive Phase 3 results for fenebrutinib, potentially the first and only BTK inhibitor for both relapsing and primary progressive multiple sclerosis, marking a major step forward for patients. With over 30 years of experience in drug discovery and development, Wendy previously served as SVP at Genentech, where she led the advancement of 25+ clinical candidates, and is a co-inventor of fenebrutinib, which has now achieved this remarkable breakthrough! @GVteam gene.com/media/press-re…